NBIX: Reading Between Lines On Company Guidance, See Room For More Beats On Crenessity

Research evidence excerpt

NBIX: Reading Between Lines On Company Guidance, See Room For More Beats On Crenessity

Neurocrine Biosciences, Inc.

Key sustainability questions

This section is intended to highlight key sustainability discussion points relevant to this company, as well as our views on the outlook. Both the

questions we highlight and our responses will evolve over time as the dialogue between management, analysts and investors continues to

advance. We welcome any feedback on the topics.

Our view

What are the most material Neurocrine continues to look for sustainability solutions, such as implementing

sustainability issues facing this green laboratory and manufacturing practices, proper clinical trial conduct including

company? ensuring diverse enrollment of patient populations, data transparency initiatives,

promotion of diversity among hires at all levels including the management team, and

socially responsible drug pricing and access to therapies for patients. The company

is also actively involved with various education and inclusion initiatives.

Does the company integrate With a clear, dedicated sustainability report that highlights the company’s active,

sustainability considerations into its direct approach to sustainability, Neurocrine stands out for its emphasis on

strategy? sustainability for a company of its size. We see well-informed initiatives closely

aligned with respectable organizations, such as the SASB and American Chemical

Society (ACS) Green Chemistry Institute Pharmaceutical Roundtable. We also see

dedicated attention from senior executives likely helping to cultivate a robust

sustainability culture and guide impactful sustainability initiatives at Neurocrine.

Overall, we believe Neurocrine is a leader in the sector for integrating sustainability